[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20060542L - Modifiserte human IGF-1R antistoffer - Google Patents

Modifiserte human IGF-1R antistoffer

Info

Publication number
NO20060542L
NO20060542L NO20060542A NO20060542A NO20060542L NO 20060542 L NO20060542 L NO 20060542L NO 20060542 A NO20060542 A NO 20060542A NO 20060542 A NO20060542 A NO 20060542A NO 20060542 L NO20060542 L NO 20060542L
Authority
NO
Norway
Prior art keywords
antibodies
human igf
modified human
igf
human
Prior art date
Application number
NO20060542A
Other languages
English (en)
Inventor
Vahe Bedian
Bruce David Cohen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20060542L publication Critical patent/NO20060542L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår humane antistoffer, for eksempel de rettet mot den humane IGF-1-reseptor (IGF-1 R) som er for behandling av kreft, som har én eller flere valgte muterte rester erstattet med kimlinjerester. En erstattet rest kan være en somatisk mutasjon i en rammeverk region.
NO20060542A 2003-08-13 2006-02-02 Modifiserte human IGF-1R antistoffer NO20060542L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49520003P 2003-08-13 2003-08-13
PCT/IB2004/002555 WO2005016967A2 (en) 2003-08-13 2004-08-03 Modified human igf-1r antibodies

Publications (1)

Publication Number Publication Date
NO20060542L true NO20060542L (no) 2006-05-03

Family

ID=34193291

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060542A NO20060542L (no) 2003-08-13 2006-02-02 Modifiserte human IGF-1R antistoffer

Country Status (37)

Country Link
US (2) US7371378B2 (no)
EP (1) EP1656391B1 (no)
JP (1) JP4638870B2 (no)
KR (1) KR100825156B1 (no)
CN (1) CN1835975B (no)
AP (1) AP2006003510A0 (no)
AR (1) AR045247A1 (no)
AT (1) ATE484525T1 (no)
AU (1) AU2004265152A1 (no)
BR (1) BRPI0413466A (no)
CA (1) CA2535071A1 (no)
CL (1) CL2004002035A1 (no)
CR (1) CR8233A (no)
DE (1) DE602004029581D1 (no)
DK (1) DK1656391T3 (no)
EA (1) EA200600234A1 (no)
EC (1) ECSP066359A (no)
ES (1) ES2351395T3 (no)
GT (1) GT200400158A (no)
IL (1) IL173273A (no)
IS (1) IS8266A (no)
MA (1) MA27988A1 (no)
MX (1) MXPA06001634A (no)
NL (1) NL1026829C2 (no)
NO (1) NO20060542L (no)
OA (1) OA13234A (no)
PA (1) PA8608801A1 (no)
PE (1) PE20050339A1 (no)
PL (1) PL1656391T3 (no)
PT (1) PT1656391E (no)
RS (1) RS20060099A (no)
TN (1) TNSN06050A1 (no)
TW (1) TWI294915B (no)
UA (1) UA85058C2 (no)
UY (1) UY28464A1 (no)
WO (1) WO2005016967A2 (no)
ZA (1) ZA200601231B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2194067B1 (en) 2001-01-05 2017-12-06 Pfizer Inc. Antibodies to insulin-like growth factor I receptor (IGF-IR)
NZ536475A (en) 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AP2006003510A0 (en) * 2003-08-13 2006-02-28 Pfizer Prod Inc Modified human IGF-1R antibodies.
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
EP2322217A3 (en) * 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US7811562B2 (en) 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0500417D0 (en) * 2005-01-10 2005-02-16 Cambridge Antibody Tech Method of mutagenesis
CA2604393A1 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
EP1896505A2 (en) * 2005-06-15 2008-03-12 Schering Corporation Anti-igf1r antibody formulations
KR101246428B1 (ko) 2005-06-17 2013-03-21 필라델피아 헬스 앤드 에듀케이션 코포레이션 디/비/에이 드렉셀 유니버시티 컬리지 오브 메디슨 항－ＰＤＧＦＲα 항체를 이용하여 이차 골 종양을 치료하는 방법
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
KR101353706B1 (ko) * 2006-02-03 2014-02-18 유니버시티 오브 워싱톤 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제
MX2008012295A (es) * 2006-03-28 2008-10-09 Hoffmann La Roche Formulacion de un anticuerpo monoclonal humano anti-igf-1r.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
KR20090023423A (ko) 2006-06-02 2009-03-04 화이자 프로덕츠 인코포레이티드 순환 종양 세포 분석
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
CA2679548C (en) * 2007-03-02 2015-01-27 Amgen Inc. Methods and compositions for treating tumor diseases
AU2012203443B2 (en) * 2007-03-02 2014-03-06 Amgen Inc. Methods and compositions for treating tumor diseases
CA2681743A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
WO2008144345A2 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
EP2225273B1 (en) 2007-12-21 2012-05-23 Roche Glycart AG Stability testing of antibodies
MX2010010480A (es) * 2008-03-25 2010-10-15 Schering Corp Metodos de tratamiento o prevencion del cancer colorrectal.
EP2282739A2 (en) * 2008-05-05 2011-02-16 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
CA2742861A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
MX352871B (es) * 2009-12-23 2017-12-13 Esbatech Alcon Biomed Res Unit Método para disminuir inmunogenicidad.
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
ES2704223T3 (es) 2010-07-12 2019-03-15 Pfizer Healthcare Ireland Conjugados de anticuerpos multifuncionales
EP2671082B1 (en) 2011-02-02 2020-01-15 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
TR201905909T4 (tr) 2011-04-19 2019-05-21 Pfizer Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
WO2013056069A1 (en) 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
US20130323234A1 (en) * 2012-01-09 2013-12-05 Covx Technologies Ireland Limited Mutant antibodies and conjugation thereof
EP2631653A1 (en) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
SG11201502937PA (en) * 2012-11-06 2015-06-29 Medimmune Llc COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES
EP2992012B1 (en) 2013-04-29 2019-07-17 F.Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
CN103319598B (zh) * 2013-05-13 2014-10-22 杭州德同生物技术有限公司 抗胰岛素样生长因子-1受体抗体及其编码基因和应用
CN105916880B (zh) 2014-01-15 2020-01-17 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
EP3484925B1 (en) * 2017-07-27 2020-05-27 iTeos Therapeutics SA Anti-tigit antibodies
WO2019117685A2 (ko) 2017-12-14 2019-06-20 에이비엘바이오 주식회사 항-igf1r 항체 및 그 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
IL118626A0 (en) 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
WO1998003516A1 (en) 1996-07-18 1998-01-29 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
CA2264284A1 (en) 1996-08-23 1998-02-26 Ralph P. Robinson Arylsulfonylamino hydroxamic acid derivatives
BR9910511A (pt) 1998-05-15 2001-11-20 Imclone Systems Inc Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
SI2168984T1 (sl) 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
ES1042735Y (es) 1999-04-07 2000-02-16 Martinez Fernando Martinez Vehiculo tripersonal de accionamiento a pedales.
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
DE10033869C2 (de) 2000-07-12 2003-07-31 Karlsruhe Forschzent HTS-Kryomagnet und Aufmagnetisierungsverfahren
EP2194067B1 (en) * 2001-01-05 2017-12-06 Pfizer Inc. Antibodies to insulin-like growth factor I receptor (IGF-IR)
PT1361893E (pt) 2001-02-19 2013-01-24 Merck Patent Gmbh Anticorpos anti-rfce modificados com imunogenicidade reduzida
DE60312639T2 (de) 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
JP4335130B2 (ja) 2002-04-30 2009-09-30 協和発酵キリン株式会社 ヒトインスリン様成長因子に対する抗体
NZ536475A (en) * 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
AU2004212344B2 (en) 2003-02-13 2009-05-07 Pfizer Products Inc. Uses of anti-insulin-like growth factor I receptor antibodies
BRPI0408317A (pt) 2003-03-14 2006-03-07 Pharmacia Corp anticorpos do receptor de igf-i para o tratamento de cáncer
WO2004087756A2 (en) 2003-04-02 2004-10-14 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
AP2006003510A0 (en) * 2003-08-13 2006-02-28 Pfizer Prod Inc Modified human IGF-1R antibodies.

Also Published As

Publication number Publication date
JP2007527705A (ja) 2007-10-04
PL1656391T3 (pl) 2011-03-31
NL1026829A1 (nl) 2005-02-15
US20050069539A1 (en) 2005-03-31
CN1835975B (zh) 2012-11-21
TWI294915B (en) 2008-03-21
ECSP066359A (es) 2006-10-31
CL2004002035A1 (es) 2005-06-03
UY28464A1 (es) 2005-03-31
KR20060035796A (ko) 2006-04-26
IL173273A (en) 2011-10-31
US7371378B2 (en) 2008-05-13
AP2006003510A0 (en) 2006-02-28
PT1656391E (pt) 2010-12-06
NL1026829C2 (nl) 2005-07-05
GT200400158A (es) 2005-07-22
US20080181891A1 (en) 2008-07-31
OA13234A (en) 2006-12-13
PE20050339A1 (es) 2005-05-17
WO2005016967A3 (en) 2005-04-14
KR100825156B1 (ko) 2008-04-24
JP4638870B2 (ja) 2011-02-23
UA85058C2 (ru) 2008-12-25
EP1656391A2 (en) 2006-05-17
EP1656391B1 (en) 2010-10-13
TW200516145A (en) 2005-05-16
RS20060099A (en) 2008-08-07
MXPA06001634A (es) 2006-04-28
CN1835975A (zh) 2006-09-20
MA27988A1 (fr) 2006-07-03
AR045247A1 (es) 2005-10-19
IS8266A (is) 2006-01-26
AU2004265152A1 (en) 2005-02-24
IL173273A0 (en) 2006-06-11
ES2351395T3 (es) 2011-02-04
ZA200601231B (en) 2007-05-30
CA2535071A1 (en) 2005-02-24
BRPI0413466A (pt) 2006-10-17
TNSN06050A1 (fr) 2007-10-03
WO2005016967A2 (en) 2005-02-24
ATE484525T1 (de) 2010-10-15
DK1656391T3 (da) 2011-01-03
DE602004029581D1 (de) 2010-11-25
PA8608801A1 (es) 2005-03-03
EA200600234A1 (ru) 2006-08-25
US7575746B2 (en) 2009-08-18
CR8233A (es) 2007-01-18

Similar Documents

Publication Publication Date Title
NO20060542L (no) Modifiserte human IGF-1R antistoffer
NO20082167L (no) Anti-Myostatin-antistoffer
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20073182L (no) Indazol-karboksamidforbindelser
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
CA2620129C (en) Diaminopyrimidines as p2x3 and p2x2/3 modulators
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
NO20064826L (no) Indazoler, benzotiazoler, benzoisotiazoler, benzisoksazoler og fremstilling og anvendelse derav
MY141867A (en) Substituted pyrimidines useful as protein kinase inhibitors
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
NO20084878L (no) Humanisert C-kit antistoff
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
MY153719A (en) Prokineticin 1 receptor antagonists
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser
WO2020097127A3 (en) B-cell activating cd73 antibodies
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
EA200701867A1 (ru) Хинолиноновые соединения в качестве агонистов рецептора 5-ht
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
EA201001872A1 (ru) Новые способы получения производных циклопропиламида

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application